PCR Detection of DNA and RNA Sequence Alterations

Slide 1 · PCR Detection of DNA and RNA Sequence Alterations

Principles, analytical readouts, and diagnostic applications

Molecular genetic diagnosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Explain how primers and repeated thermal cycles amplify a defined DNA target.

Distinguish sequencing, restriction analysis, amplicon sizing, and quantitative PCR.

Select a PCR-based readout for known sequence variants, repeat alterations, or molecular burden.

Recognize assay limitations and interpret negative findings in clinical context.

Known target

Amplification

Sequence

Fragment size

Target amount

Three different readout questions

Slide 3 · PCR as a platform for molecular diagnosis

PCR amplifies a selected DNA fragment before further molecular analysis.

A defined target can be enriched from a very small quantity of starting DNA.

Amplification is a preparation step; The readout determines which alteration is detected.

Many molecular diagnoses combine PCR with a second analytical technique.

Known target

Amplification

Sequence

Fragment size

Target amount

Three different readout questions

Slide 4 · The clinical question determines the assay

Identify whether the desired result is sequence identity, fragment size, or target quantity.

Ask whether the lesion is known and localized or potentially large and complex.

Choose an appropriate specimen containing the genetic material of interest.

A technically successful test is useful only if it addresses the suspected abnormality.

What is the lesion?

What material is available?

Which readout is needed?

Slide 5 · Genetic alterations occur at different scales

Single-nucleotide substitutions alter base identity without necessarily changing product length.

Small insertions, deletions, and repeat expansions may change amplicon size.

Large deletions and complex rearrangements may lie outside a practical PCR assay.

No single readout detects every class of molecular lesion equally well.

Single-base change

Short insertion / deletion

Large rearrangement

PCR is most straightforward for a defined short target

Slide 6 · Constitutional and somatic alterations

Constitutional variants are present throughout the patient’s body.

Somatic variants may be confined to tumor tissue or another affected compartment.

The same assay principle can apply to inherited and acquired disease.

A sample lacking the altered cell population can yield an uninformative result.

Constitutional variant

Somatic variant

Present throughout

Body cells

Restricted to a

Tissue or lesion

Specimen choice follows biological distribution

Slide 7 · Specimen selection is part of test design

Peripheral blood is commonly used when a constitutional genetic disorder is suspected.

Tumor tissue can provide the somatic alteration sought in a cancer assay.

Swabs and other infected specimens can be used to identify pathogen nucleic acid.

Assay selection and specimen choice must match the biology of the lesion.

Blood DNA

Tumor tissue

Swab / fluid

Target-specific assay

Sampling the wrong compartment can miss the target

Slide 8 · PCR begins with a DNA template

Conventional PCR amplifies DNA—not RNA directly.

Genomic DNA can serve as template when the target is encoded in the genome.

RNA measurements require reverse transcription into complementary DNA (cDNA).

The distinction matters when detecting transcripts rather than genomic lesions.

DNA template

RNA template

Direct PCR

CDNA → PCR

Reverse transcription converts RNA into DNA

Slide 9 · Core components of a PCR reaction

Template DNA contains the sequence to be amplified.

A pair of synthetic primers defines the flanking sequences of the target.

A heat-stable DNA polymerase extends complementary DNA strands.

Repeated temperature changes coordinate strand separation and primer binding.

Template DNA

Primers

Heat-stable polymerase

Thermal cycling

Target lies between the primer-binding sites

Slide 10 · Two primers define the amplicon

One primer anneals on each side of the selected target region.

Primer orientation allows synthesis across the intervening sequence.

The region between primer-binding sites is enriched during cycling.

A mutation affecting primer binding can compromise target recovery.

Forward primer →

← Reverse primer

Amplicon

Illustrative primer positions; Not genomic coordinates

Slide 11 · Thermal cycling has three logical stages

Denaturation separates the paired DNA strands.

Annealing permits each primer to bind its complementary template.

Extension produces a new complementary strand from the bound primer.

Repetition produces progressively more copies of the target region.

Denature

Strands

Anneal

Primers

Extend

DNA

Repeated thermal cycling enriches the defined segment

Slide 12 · Denaturation makes templates accessible

Double-stranded DNA is separated into single strands by heating.

Both original and newly synthesized strands become templates in later cycles.

The process is necessary before primers can access their complementary sites.

Denaturation is an enabling step rather than the sequence-detection readout.

Two strands separate so primers can bind

Slide 13 · Annealing specifies the target

Primers bind to complementary sequences flanking the region of interest.

Specificity is governed by where these primer sequences hybridize.

A target outside the primer-defined interval is not interrogated by this amplicon.

Primer-site alterations can contribute to failure to amplify an allele.

Primer binding identifies boundaries

Primers hybridize to complementary target sites

Slide 14 · Polymerase extension copies the target

A heat-stable polymerase remains functional over repeated thermal cycles.

From a bound primer, the enzyme synthesizes a complementary DNA strand.

New strands can participate as templates in subsequent cycles.

Amplification increases the material available for analysis.

Polymerase extends from primer ends

New complementary strands are synthesized

Slide 15 · Repeated cycles lead to large enrichment

Each newly created target can contribute template in a later cycle.

Amplification can be exponential during the efficient early phases.

Amplification may begin from as little as a single template copy.

Idealized doubling is a conceptual model, not a guaranteed clinical yield.

Cycle 0

Cycle 1

Cycle 2

Cycle 3

Idealized doubling; Real reactions eventually depart from this

Schematic — not patient or laboratory data

Slide 16 · PCR is usually applied to defined short regions

The Robbins discussion focuses on relatively short DNA targets, usually under about 1000 bp.

A defined amplicon is well suited to localized sequence interrogation.

Long or difficult regions may not amplify under standard assay conditions.

Amplicon design imposes a boundary on what an assay can report.

Defined flanking sites

Short amplicon

Typical targets as under ~1 kb

Slide 17 · PCR amplification is not a mutation call

A visible PCR product establishes that a target-sized fragment was amplified.

Sequence changes may leave product length unchanged.

Post-amplification sequencing can reveal the order of nucleotide bases.

Digestion or length measurements answer different, narrower questions.

PCR product

Sanger

Base order

Restriction

Cut pattern

Length

Size

Slide 18 · Four readouts highlighted by Robbins

Approach

Primary observation

Useful target

Sanger sequencing

Order of bases in a PCR product

Localized sequence changes

Restriction fragment analysis

Pattern after sequence-specific digestion

Known variant at enzyme cut site

Amplicon length analysis

Size of amplified fragment

Small indels or repeat-length changes

Real-time quantitative PCR

Fluorescent signal during amplification

Target burden / transcript abundance

Readout selection should follow the suspected lesion and clinical purpose.

Slide 19 · Sanger sequencing: The central question

What is the nucleotide sequence within the amplified target?

A single PCR amplicon can be submitted to a sequencing reaction.

The measured sequence is aligned with a reference for variant detection.

This approach is broader than a test asking only about one restriction site.

PCR amplicon

Sequencing reaction

Length separation

Base calls

Slide 20 · Sanger sequencing reaction components

The reaction uses one primer together with DNA polymerase and a DNA template.

Ordinary nucleotides permit extension of the new DNA strand.

Four differently labeled dideoxy terminators correspond to A, T, G, and C.

Terminator incorporation stops extension and labels the ending base.

Single primer

Polymerase

Ordinary nucleotides

Fluorescent ddNTPs

All components interrogate one defined template

Slide 21 · Dideoxy terminators interrupt synthesis

A dideoxy nucleotide can be incorporated during DNA synthesis.

Once incorporated, the terminated molecule cannot be extended further.

Different reaction molecules terminate at different positions.

The terminal fluorescent label identifies the base at that stopping site.

A terminator stops extension at its incorporated base

Colors represent the labeled terminator identities

Slide 22 · The reaction generates a length ladder

Products are generated at a range of lengths from the same starting template.

Each terminated product carries a fluorescently labeled final nucleotide.

The size ladder preserves positional information about the base sequence.

This mixture must be ordered by length to reconstruct the nucleotide sequence.

Short

Long

Illustrative length-ordered fragment mixture

Schematic — not patient or laboratory data

Slide 23 · Electrophoretic separation orders fragments

Sequencing products are separated according to their lengths.

Reading labels in the resulting length order recovers the base calls.

The output describes one defined amplified region, not the whole genome.

Quality depends on a usable amplicon and an interpretable sequencing reaction.

Short

Long

Illustrative length-ordered fragment mixture

Schematic — not patient or laboratory data

Slide 24 · A sequence is read one base at a time

Each length-position is associated with an A, T, G, or C fluorescence label.

Together, these labels allow reconstruction of a nucleotide sequence.

Base order—not fragment length alone—is the useful diagnostic observation.

The resulting sequence must be interpreted against a reference.

A

G

T

C

A

T

G

C

Example base-order display; Not a sequencing trace

Schematic — not patient or laboratory data

Slide 25 · Reference comparison reveals a substitution

A base substitution can be recognized when sample and reference differ at one position.

The illustrative C-to-T change does not alter total amplicon length.

Consequently, simple fragment sizing would not reveal this example.

Reference

ATG C T A A G

Sample

ATG T T A A G

C → T

Hypothetical substitution; No patient sequence implied

Schematic — not patient or laboratory data

Slide 26 · What Sanger sequencing can and cannot answer

It directly describes nucleotide order across the amplified region.

It can identify a localized sequence change not predicted in advance.

It is limited by the region amplified and submitted for sequencing.

Large or complex genomic changes require consideration of other methods.

PCR amplicon

Sequencing reaction

Length separation

Base calls

Slide 27 · Restriction fragment analysis: Principle

Restriction endonucleases cut DNA at particular recognition sequences.

A known variant may create or disrupt a recognition site.

Digestion can then yield a different set of product lengths.

The diagnostic signal is an electrophoretic fragment pattern.

Known variant at a cut site

Digest PCR product

Fragment lengths report whether cutting occurred

Slide 28 · A restriction enzyme recognizes a sequence

Enzyme binding is determined by a specific nucleotide sequence.

When the recognition site is present, the DNA product can be cut.

A change in that sequence may prevent the normal cut.

Whether a variant affects the site must be established before using this assay.

Recognition site

Diagram is conceptual, not a specific restriction enzyme

Slide 29 · Restriction analysis workflow

Amplify the locus containing the relevant recognition site.

Expose the amplified material to the chosen restriction enzyme.

Separate digested fragments by gel electrophoresis.

Compare observed band patterns with the patterns expected from the alleles.

Known variant at a cut site

Digest PCR product

Fragment lengths report whether cutting occurred

Slide 30 · Cut versus uncut products yield different bands

Cut DNA produces shorter fragments than an otherwise uncut product.

Mixtures of product classes may yield multiple bands in a lane.

Fragment sizes depend on the actual assay design and restriction site.

The diagram illustrates logic only and contains no laboratory measurements.

Uncut

Cut

Mixture

Conceptual gel bands; Not measured fragment lengths

Schematic — not patient or laboratory data

Slide 31 · Restriction analysis is deliberately targeted

It is useful when a mutation is known to alter a specific cut site.

The assay asks whether a predicted restriction pattern is present.

Other variants that leave the site unchanged may go undetected.

This narrower scope explains why restriction analysis is less comprehensive than sequencing.

Sequence change

Cut site altered

Different fragment pattern

Best for a known, recurrent variant

Slide 32 · Sanger versus restriction analysis

Feature

Sanger sequencing

Restriction analysis

Direct output

Nucleotide base sequence

Cut / uncut fragment pattern

Prior variant knowledge

Not always needed for any variation in target

Known relevant cut-site change

Readout

Fluorescence by fragment length

Gel bands after digestion

Important limitation

Only the amplified region

Only sequence changes affecting cut pattern

Both approaches usually begin with targeted amplification.

Slide 33 · Amplicon length analysis: Principle

Some deletions, insertions, and repeat expansions change the distance between primers.

The resulting amplicons differ in length if each form can be amplified.

Size separation can distinguish products without sequencing every base.

A single-base substitution may produce no length difference.

Shorter allele

Longer allele

Length contrasts are illustrative; No scale is implied

Slide 34 · Length analysis cannot determine base identity

Two sequences can have the same length yet differ in nucleotide composition.

Sizing is therefore suitable for size-altering lesions, not arbitrary substitutions.

The method is particularly useful when the length change is the diagnostic signal.

The expected sizes must be interpreted using the assay design.

Shorter allele

Longer allele

Length contrasts are illustrative; No scale is implied

Slide 35 · Repeat-length variation changes product size

Tandem repeats contain recurring sequence units arranged end to end.

A different number of repeat units changes the distance between flanking primers.

An amplifiable repeat interval therefore generates a different-sized fragment.

Repeat copy number is inferred from the size relationship, not from a displayed micrograph.

Flanking primer

Repeat region

Flanking primer

Each repeat contributes to amplified length

Schematic — not patient or laboratory data

Slide 36 · Primer design around a repeat tract

The primers must lie outside the variable-length repeated region.

Each amplified allele includes the intervening repeat tract.

Changes in the tract alter product length while primer positions remain fixed.

Amplification failures complicate interpretation of very large expansions.

Flanking primer

Repeat region

Flanking primer

Each repeat contributes to amplified length

Schematic — not patient or laboratory data

Slide 37 · FMR1 is a clinical example of repeat analysis

A trinucleotide-repeat region at the 5′ end of FMR1.

Different repeat counts in normal and premutation alleles can alter PCR product length.

Gel electrophoresis may distinguish products from alleles that amplify.

PCR alone may not resolve the largest expansions relevant to fragile X syndrome.

FMR1 5′ repeat region

Different repeat counts

Products from amplifiable alleles differ in size

Slide 38 · Fragile X repeat analysis has a PCR blind spot

Very large repeat expansions may not amplify with conventional PCR.

Failure to recover an expanded allele can make a size-only result incomplete.

Southern blot analysis as a possible complementary method.

A missing product must not automatically be interpreted as a normal-sized repeat.

Very large repeat expansion

Conventional PCR may fail

Absence of product is not proof of absence of expansion

Slide 39 · When complementary testing is needed

Start from the clinical question and expected lesion size.

Conventional amplicon sizing works only when relevant allele forms amplify.

If a very large FMR1 expansion is suspected, Southern blot may be required.

Interpret an apparently negative result in the context of assay reach.

Question: Repeat expansion?

PCR size analysis

Southern blot if very large

Slide 40 · Deletion and expansion can both alter length

Deletion of sequence between primers can shorten the amplified product.

An insertion or repeat expansion may lengthen the amplified interval.

Allele sizes do not, by themselves, identify exact deleted or inserted bases.

Sequencing provides different information from the length readout.

Shorter allele

Longer allele

Length contrasts are illustrative; No scale is implied

Slide 41 · Length analysis versus sequence analysis

Diagnostic question

Fragment sizing

Sanger sequence

Is the product shorter or longer?

Directly informative

May be informative

Which base was substituted?

Usually not informative

Directly informative

How many repeat units?

Can infer if alleles amplify

May be challenging for large repeats

What lies outside PCR primers?

Not interrogated

Not interrogated

Targeted methods inherit the boundaries established by their primers.

Slide 42 · Real-time PCR asks a quantitative question

The objective is to detect and quantify a defined nucleic acid target.

Fluorescent indicators report product accumulation during cycling.

Assessment during the exponential amplification phase.

Monitoring molecular burden is a central clinical use.

Cycle and amplify

Detect fluorescence

Assess target during amplification

Slide 43 · Endpoint PCR versus real-time PCR

Endpoint analysis examines the products after the reaction is completed.

Real-time analysis interrogates fluorescent signal during amplification.

This allows quantitative assessment of the target rather than size alone.

Readout choice should reflect whether the clinical question is presence or burden.

Endpoint PCR

Real-time qPCR

Analyze after cycling

Measure during cycling

Readout timing changes what is measured

Slide 44 · Fluorescence provides the qPCR signal

Fluorophore-based technologies make target-associated amplification detectable.

Signal acquisition occurs during repeated PCR cycles.

The measured signal is interpreted using the assay’s quantitative framework.

The fluorescence mechanism should not be confused with Sanger base labeling.

Target material

Fluorescent signal

Quantification

Interpret with appropriate assay design and context

Slide 45 · The exponential phase is analytically important

The exponential phase as the period for real-time assessment.

Amplification products accumulate across successive cycles.

QPCR relies on the relationship between product accumulation and fluorescent detection.

Clinical quantitative results depend on validated assay design and interpretation.

Cycle 0

Cycle 1

Cycle 2

Cycle 3

Idealized doubling; Real reactions eventually depart from this

Schematic — not patient or laboratory data

Slide 46 · RNA targets require reverse transcription

RNA is converted to complementary DNA before conventional DNA amplification.

The resulting cDNA can then serve as PCR or qPCR template.

This enables analysis of RNA species, including disease-associated transcripts.

Reverse transcription changes template type; It does not by itself sequence RNA.

RNA

Complementary DNA

PCR / qPCR

Reverse transcription must precede DNA polymerase amplification

Slide 47 · RT-PCR and qPCR describe different steps

RT-PCR denotes PCR preceded by reverse transcription of RNA into cDNA.

QPCR denotes real-time quantitative measurement during amplification.

The same workflow may combine reverse transcription with quantitative PCR.

Precise naming avoids conflating RNA template preparation with quantification.

DNA template

RNA template

Direct PCR

CDNA → PCR

Reverse transcription converts RNA into DNA

Slide 48 · BCR–ABL transcript monitoring in CML

Chronic myeloid leukemia has a characteristic BCR–ABL fusion lesion.

BCR–ABL fusion mRNA as an example of a quantitative RNA target.

Reverse transcription produces a cDNA template for quantitative analysis.

Serial molecular measurement can inform treatment efficacy and disease burden.

BCR–ABL fusion mRNA

Reverse transcription

Quantitative PCR monitoring

Slide 49 · PCR-based monitoring differs from diagnosis

At diagnosis, the question may be whether a disease-associated lesion is present.

During follow-up, the question may be how much of a molecular target persists.

The same target can therefore support more than one clinical decision.

A quantitative trend should be interpreted within the defined disease context.

BCR–ABL fusion mRNA

Reverse transcription

Quantitative PCR monitoring

Slide 50 · Viral nucleic-acid burden is another qPCR use

HIV and Epstein–Barr virus as clinical examples of viral-load assessment.

The assay targets microorganism-associated nucleic acid in an appropriate specimen.

Quantitative monitoring can contribute to evaluation of infection or treatment.

Whether reverse transcription is required depends on whether the target is RNA.

Patient-derived sample

Viral nucleic acid

Quantitative molecular readout

Slide 51 · Cancer and infection share the PCR framework

Clinical setting

Target example

Question addressed

CML

BCR–ABL fusion mRNA

How much molecular disease signal?

Infectious disease

HIV-related viral nucleic acid

What is the viral burden?

Infectious disease

Epstein–Barr virus DNA

What is the viral burden?

Inherited disease

FMR1 repeat-containing DNA

How large is the repeat amplicon?

These are textbook examples of PCR applications, not universal testing guidelines.

Slide 52 · DNA targets and RNA targets are not interchangeable

Genomic DNA assays analyze material encoded in DNA.

RNA assays interrogate a transcribed or viral RNA target only after reverse transcription.

BCR–ABL fusion mRNA and genomic lesions may answer different questions.

Assay wording should specify the measured molecule and intended clinical use.

DNA template

RNA template

Direct PCR

CDNA → PCR

Reverse transcription converts RNA into DNA

Slide 53 · Every method has a defined detection scope

Sanger sequencing describes sequence within one amplified region.

Restriction assays depend on an informative cut-site change.

Size assays require both length change and successful amplification.

Quantitative PCR measures abundance of a selected target, not every possible mutation.

Question: Identity / length / quantity?

Sequence → Sanger

Cut site → restriction

Length → sizing

Abundance → qPCR

Slide 54 · Analytical performance influences method choice

Sensitivity, specificity, accuracy, and reproducibility.

Cost, labor, reliability, and turnaround time also shape assay choice.

A method must match the spectrum of lesions in the population tested.

Performance characteristics are assay-specific rather than guaranteed by the term PCR.

What is the lesion?

What material is available?

Which readout is needed?

Slide 55 · A negative targeted assay does not exclude disease

A patient may harbor a lesion outside the amplified interval.

A suspected repeat expansion may be too large for conventional PCR.

Large deletions and rearrangements may require other technologies.

Persistently high clinical suspicion justifies reconsidering test selection.

Negative targeted PCR

High clinical suspicion persists

Consider complementary assay

Slide 56 · PCR does not readily resolve every structural lesion

Large deletions, duplications, and complex rearrangements.

Such lesions may have variable breakpoints that are poorly suited to targeted PCR.

Hybridization-based or other genomic methods can address complementary questions.

The practical limitation is locus coverage, not a universal failure of PCR chemistry.

Short defined locus

Large complex lesion

Often PCR-friendly

May need another method

Assay reach follows genomic alteration scale

Slide 57 · Selecting a PCR readout by abnormality

Suspected alteration

Appropriate initial readout

Key limitation

Localized unknown base change

Sanger sequencing

Only sequenced amplicon

Known cut-site variant

Restriction fragment pattern

Variant must alter enzyme recognition

Amplifiable repeat-size change

Amplicon size analysis

Large allele may fail amplification

Transcript / viral burden

Real-time qPCR (RT step for RNA)

Target- and assay-specific quantification

The table maps the molecular question to the textbook-described assay principle.

Slide 58 · Integrated clinical molecular workflow

Define the suspected disease and likely class of genetic alteration.

Obtain material likely to contain the constitutional, somatic, or microbial target.

Choose primer-defined amplification and an informative analytical readout.

Review test limitations before translating findings into clinical conclusions.

Clinical suspicion

Assay selected for lesion type

Result interpreted in context

Slide 59 · Case: An invariant pathogenic cut-site variant

A familial disorder is known to involve a fixed nucleotide change affecting a restriction site.

The laboratory needs an efficient targeted assay for the known alteration.

Which post-PCR method directly exploits altered enzyme cleavage?

Why would this method not serve as a general screen for all variants?

Sequence change

Cut site altered

Different fragment pattern

Best for a known, recurrent variant

Slide 60 · Case answer: Use restriction fragment analysis

PCR amplifies a defined interval containing the altered recognition site.

Restriction digestion produces the expected allele-dependent fragment pattern.

Electrophoresis distinguishes cut and uncut classes.

The approach is appropriate because the causal variant and informative site are known.

Uncut

Cut

Mixture

Conceptual gel bands; Not measured fragment lengths

Schematic — not patient or laboratory data

Slide 61 · Case: Same-sized DNA products, different bases

Two samples produce amplicons of equal length.

A single-base substitution is suspected within the amplified locus.

Amplicon sizing cannot establish the sequence difference.

Which method allows the base order to be compared with a reference?

Reference

ATG C T A A G

Sample

ATG T T A A G

C → T

Hypothetical substitution; No patient sequence implied

Schematic — not patient or laboratory data

Slide 62 · Case answer: Use Sanger sequencing

Sequence a defined PCR product with terminator-labeled extension reactions.

Size-separate the terminated products to recover nucleotide order.

Compare the sample sequence against the relevant reference.

The length match does not rule out a nucleotide substitution.

PCR amplicon

Sequencing reaction

Length separation

Base calls

Slide 63 · Case: Possible large FMR1 expansion

Clinical suspicion of fragile X syndrome remains high.

Conventional PCR detects no clearly expanded product.

The missing band cannot be interpreted as definitive absence of an expansion.

Which complementary assay does Robbins identify for very large expansions?

Very large repeat expansion

Conventional PCR may fail

Absence of product is not proof of absence of expansion

Slide 64 · Case answer: Consider Southern blot

The largest trinucleotide expansions may exceed conventional PCR amplification capability.

Southern blotting of genomic DNA may therefore be required.

The choice addresses an assay limitation rather than negating PCR utility.

Test reporting should state the detection limits relevant to the suspected lesion.

Question: Repeat expansion?

PCR size analysis

Southern blot if very large

Slide 65 · Case: Monitoring molecular disease in CML

A patient with CML undergoes serial assessment for a BCR–ABL fusion transcript.

The target being measured is RNA rather than genomic DNA.

Reverse transcription prepares the template for amplification.

Quantitative PCR provides a molecular burden readout for follow-up.

BCR–ABL fusion mRNA

Reverse transcription

Quantitative PCR monitoring

Slide 66 · Five concepts that govern PCR interpretation

Primers determine which DNA interval is interrogated.

The downstream analytical readout determines what constitutes a result.

RNA is converted into cDNA before PCR.

Large repeats and rearrangements create predictable detection gaps.

Clinical interpretation requires the correct specimen and a disease-specific question.

Question: Identity / length / quantity?

Sequence → Sanger

Cut site → restriction

Length → sizing

Abundance → qPCR

Slide 67 · References and source boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. (2026). Chapter 5: Genes and Human Diseases.

Primary section: “PCR Detection of DNA and RNA Sequence Alterations,” printed p. 161.

Parent section: “Molecular Genetic Diagnosis,” printed pp. 159–161.

The molecular schemes and sequence examples are newly constructed educational illustrations.

Original textbook Figure 5.33 and chapter PDF were unavailable for direct comparison; no figure is reproduced.